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Abstract
Background: We used lentiviral vectors (LVs) to generate a new SCA7 animal model overexpressing a truncated
mutant ataxin-7 (MUT ATXN7) fragment in the mouse cerebellum, in order to characterize the specific
neuropathological and behavioral consequences of the genetic defect in this brain structure.
Results: LV-mediated overexpression of MUT ATXN7 into the cerebellum of C57/BL6 adult mice induced
neuropathological features similar to that observed in patients, such as intranuclear aggregates in Purkinje
cells (PC), loss of synaptic markers, neuroinflammation, and neuronal death. No neuropathological changes
were observed when truncated wild-type ataxin-7 (WT ATXN7) was injected. Interestingly, the local delivery
of LV-expressing mutant ataxin-7 (LV-MUT-ATXN7) into the cerebellum of wild-type mice also mediated the
development of an ataxic phenotype at 8 to 12 weeks post-injection. Importantly, our data revealed abnormal
levels of the FUS/TLS, MBNL1, and TDP-43 RNA-binding proteins in the cerebellum of the LV-MUT-ATXN7
injected mice. MUT ATXN7 overexpression induced an increase in the levels of the pathological phosphorylated TDP-43,
and a decrease in the levels of soluble FUS/TLS, with both proteins accumulating within ATXN7-positive intranuclear
inclusions. MBNL1 also co-aggregated with MUT ATXN7 in most PC nuclear inclusions. Interestingly, no MBNL2
aggregation was observed in cerebellar MUT ATXN7 aggregates. Immunohistochemical studies in postmortem
tissue from SCA7 patients and SCA7 knock-in mice confirmed SCA7-induced nuclear accumulation of FUS/TLS
and MBNL1, strongly suggesting that these proteins play a physiopathological role in SCA7.
Conclusions: This study validates a novel SCA7 mouse model based on lentiviral vectors, in which strong and
sustained expression of MUT ATXN7 in the cerebellum was found sufficient to generate motor defects.
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Background
Spinocerebellar ataxia type 7 (SCA7) is an inherited auto-
somal dominant neurodegenerative disorder. Patients
present with cerebellar ataxia due to moderate to severe
neuronal loss and gliosis in the cerebellum, especially
Purkinje cells, inferior olivary, dentate nucleus and pon-
tine nuclei, and to a lesser extent in the globus pallidus,
substantia nigra and red nucleus. They also present with
visual impairment due to degeneration of cone and rod
photoreceptors [1–3]. SCA7 is caused by an unstable
CAG repeat expansion in the coding region of the SCA7
gene conferring a toxic gain of function to the ataxin-7
(ATXN7) protein which accumulates aberrantly in neu-
rons, a mechanism also involved in a family of eight other
inherited neurodegenerative polyglutamine (PolyQ) dis-
eases, including Huntington’s disease (HD), spinobulbar
muscular atrophy (SBMA), dentatorubral pallidoluysian
atrophy (DRPLA), spinocerebellar ataxia (SCA) types 1, 2,
3, 6 and 17 [4]. ATXN7 is ubiquitously expressed in the
brain and is a component of the highly conserved tran-
scriptional coactivator Spt/Ada/Gcn5 acetylase (SAGA)
chromatin remodelling complex with histone acetyltrans-
ferase activity and deubiquitinase activity [5]. It has been
shown that the ubiquitin protease activity of SAGA is im-
portant for the expression of tissue-specific and develop-
mental genes [5]. Recently, it was shown that SAGA
acetylates the promoters and deubiquitinates the tran-
scribed regions of all expressed genes [6]. ATXN7 has
been described to be cleaved by caspase-7 at two sites [7],
generating N-terminal fragments containing the polyQ
tract, resulting in MUT ATXN7 fragments that accumu-
late in the nucleus. Indeed, a ∼ 55 kDa ATXN7 amino-
terminal fragment was previously identified in SCA7
transgenic mice and in SCA7 patients [8]. Interestingly, it
has been reported that post-translational modifications at
lysine 257, adjacent to the caspase-7 mediated cleavage
site of ATXN7 at position 266, mitigate fragment accumu-
lation in vitro and in vivo, thus regulating SCA7 toxicity
[9, 10]. ATXN7 expanded polyQ stretches result in con-
formational modifications, finally leading to the formation
of insoluble aggregates, hallmarks of SCA7 [11]. The exact
mechanism by which polyQ aggregates mediate toxicity
is still debated, but one strong hypothesis is the fact
that they may be prone to trap multiple binding part-
ners such as transcription factors, important to the
maintenance of cell homeostasis, that will in turn be
progressively depleted [3], or RNA-binding proteins
(RBPs), leading to dysregulation of alternative splicing
of target mRNAs [12, 13]. The generation of murine
genetic models that closely recapitulate the human
neuropathology are extremely valuable for the dissec-
tion of disease mechanisms and evaluation of thera-
peutic strategies. In the case of SCA7, the cloning of
the SCA7 gene allowed the creation of transgenic and
knock-in mouse models, in which cerebellar neuronal
dysfunction and progressive retinal degeneration were
directly associated to the accumulation of mutant
ATXN7 [8, 14–16], despite poor neuronal degeneration
[8, 15]. Alternatively, local overexpression of mutant
proteins using viral vectors has been a successful strat-
egy to model polyQ pathologies of the central nervous
system (CNS), such as HD [17] and SCA3 [18], generat-
ing robust in vivo genetic models leading to neuronal
degeneration in well-defined brain regions.
Here, we generated an in vivo model of SCA7 by over-
expressing truncated MUT ATXN7 in the mouse cere-
bellum using a locally injected lentiviral vector (LV). The
truncated construct we used corresponds approximately
to the caspase-7 cleavage fragment [7]. The SCA7-LV
mice developed an ataxic phenotype and this model fur-
ther allowed investigating whether specific RBPs could
be involved in the pathogenesis of SCA7. We initially fo-
cused on the RBP Fused in sarcoma (FUS/TLS), found
to be mutated in familial amyotrophic lateral sclerosis
(ALS) [19], since it was shown to be a major component
of nuclear aggregates in several polyQ disorders, such as
HD, SCA1 and SCA3 [20, 21]. We next looked for the
transactive response DNA binding protein 43-kDa
(TDP-43), pathologically associated to ALS and fronto-
temporal lobar degeneration with ubiquitinated inclusions
(FTLD-U) [22] that was also shown to be sequestered in
polyQ aggregates [23]. Finally, we investigated in this
SCA7-LV model, the cellular localization and expression
of two evolutionarily conserved RBPs that constitute part
of the muscleblind-like protein family (MBNL1 and
MBNL2) and are expressed in a wide variety of adult tis-
sues including brain, heart and skeletal muscle [24].
MBNL1 and MBNL2 associate and bind to expanded
CUG and CAG repeats, which accumulate as discrete nu-
clear foci in both DM1 and DM2 (myotonic dystrophy
type 1 and type 2) [24–26], therefore suggesting their
implication in these disorders.
We therefore investigated in the LV-based model of
SCA7 the impact of MUT ATXN7 accumulation over
the expression of the RBPs referred above. This was
complemented with immunohistochemical and biochem-
ical analyses performed in the cerebellum of a SCA7
knock-in mouse model [16] and in cerebella from SCA7
affected patients. In summary, we set up a new LV-based
model of SCA7, alternative to transgenesis, in which spe-
cific RBPs were found to be accumulated, suggesting their
role in SCA7 pathogenesis.
Results
Lentiviral-mediated MUT ATXN7 overexpression in the
mouse cerebellum triggers time-dependent aggregation
In SCA7 KI mice, mutant ATXN7 accumulates robustly
in the cerebellum [16, 27]. Since human SCA7 pathology
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strongly affects the cerebellum (reviewed in [28]), we
created a SCA7 LV-based model in which LV encoding
human ATXN7, driven by the PGK-1 (phosphoglycerate
kinase 1) promoter, is injected into the mouse cerebellum.
We first checked that intracerebellar injection of
GFP-expressing LVs allowed a sustained expression of
the transgene over a large region (~3 mm), almost
exclusively in neurons, as demonstrated herein by
GFP-immunohistochemical analysis at 12 weeks post-
injection (Additional file 1: Fig. S1).
Wild-type mice were therefore injected following simi-
lar stereotactical conditions with LVs expressing either
the wild-type (LV-ATXN7-10Q, n = 9) or the mutant
ATXN7 (LV-ATXN7-100Q, n = 11), driven by the PGK-1
(phosphoglycerate kinase-1) promoter (Fig. 1a, b). WT
ATXN7 and MUT ATXN7 were detected in the cerebel-
lum 2 weeks and 12 weeks after LV injection using an
antibody against ATXN7, thus modelling an early or late
stage of the SCA7 pathology. The intense anti-ATXN7
immunostaining revealed the production of a significant
amount of both the wild-type and mutant human pro-
tein within the PC layer and the cells of the granule and
molecular layers (Fig. 1d–g). The immunoreactivity of
truncated WT ATXN7 was mainly nuclear and diffuse at
2 weeks (Fig. 1d, i and n) and 12 weeks post-injection
(Fig. 1e, j and o). Similarly, MUT ATXN7 immunostain-
ing was nuclear and relatively diffuse at 2 weeks post-
injection (Fig. 1f and k), however the formation of early
small aggregates was already evidenced by laser confocal
microscopy (Fig. 1p). As expected, a robust nuclear and
punctuate staining of MUT ATXN7 was observed at
12 weeks post-injection (Fig. 1g, l and q), corresponding
to the nuclear ATXN7-positive inclusions, hallmarks of
SCA7. No transgenic ATXN7 was observed in mice
injected with PBS (Fig. 1c, h and m). Similar results were
obtained using anti-GFP immunohistochemistry to dis-
tinguish the human from the murine endogenous
ATXN7 (Fig. 1r–v).
Upon injection of the vectors in the mouse cerebel-
lum, truncated human WT ATXN7 and MUT ATXN7
were also detected by western-blot on tissue biopsies at
2 weeks post-injection. The level of transgenic WT
ATXN7 was ~30 times higher than endogenous murine
ATXN7, indicating that the LVs strongly overexpress
human ATXN7 in vivo. The amount of soluble trans-
genic MUT ATXN7 was lower, compared to WT
ATXN7, probably due to the strong accumulation in
the form of SDS-insoluble aggregates, observed in the
stacking gel (Fig. 1w).
In regions expressing MUT ATXN7, misfolded
ubiquitin-positive and p62 proteins co-localized with
ATXN7 in ~93 and ~80 % of nuclear inclusions at
12 weeks post-injection, as described previously in a
knock-in mouse model containing 266 glutamines [29].
In contrast, no ubiquitin or p62 accumulation was
detected in regions injected with vectors encoding trun-
cated WT ATXN7 (Additional file 1: Fig. S2).
Lentiviral-based overexpression of MUT ATXN7 in the
mouse cerebellum induces neuronal cell loss, disruption
of axons and dendrites and synaptotoxicity
We then investigated whether overexpression of MUT
ATXN7 could trigger dysfunction followed by neurode-
generation, by carrying out immunohistochemical ana-
lysis for the calbindin-D28K protein, a specific marker
for PCs (Fig. 2a–e). In MUT ATXN7-injected mice, the
immunostaining analysis performed at 2 and 12 weeks
post-injection showed either moderate (21.33 ± 2.43
cells/mm) (Fig. 2d and f) or robust loss of PCs (9.63 ±
1.13 cells/mm) (Fig. 2e and f), respectively. In contrast,
no cell loss was observed 2 weeks (28.12 ± 2.56 cells/
mm) (Fig. 2b and f) or 12 weeks post-injection (26.4 ±
0.48 cells/mm) (Fig. 2e and f) in mice that received LV-
WT-ATXN7, compared to mice injected with PBS at
12 weeks (Fig. 2a and f). Double staining for WT
ATXN7 and calbindin revealed that a high proportion of
PCs expressed the wild-type protein at 12 weeks after
LV injection, without inducing any toxicity (Fig. 2g). PC
cells also expressed MUT ATXN7 early after LV-
injection (2 weeks) (Additional file 1: Fig. S3) but not at
12 weeks post-injection most probably due to massive
PC loss (Fig. 2h).
In addition, cresyl violet stained sections (Fig. 2i–m)
showed the presence of atrophic cell nuclei (Fig. 2m)
and shrinkage of both the granule (GCL) (~31 %) and
molecular layers (ML) (~33 %) around the injection site,
only at 12 weeks post-injection in mice injected with
LV-MUT-ATXN7 (Fig. 2n and o, respectively). Finally,
neurotracer (Fig. 2p and q) and Fluorojade-B (Fig. 2r
and s) dyes were used to stain degenerating cells, and
caspase-3 (Fig. 3t and u), an apoptosis-related cysteine
peptidase, was used to label apoptotic cells: in cerebellar
regions injected with LV expressing truncated WT
ATXN7 no degenerating and/or apoptotic neurons were
observed, whereas a large number of degenerating cells
were detected in regions injected with LV expressing
truncated MUT ATXN7 (Fig. 3s and u, arrows).
Next, we examined the impact of both WT ATXN7
and MUT ATXN7 overexpression on two major neuron-
specific cytoskeletal proteins: the microtubule associated
protein 2 (MAP-2), a marker for dendritic processes,
and the neurofilament (NF) 70-kDa protein, that provide
support for normal axonal radial growth. Double stain-
ing of cerebellar sections from LV-MUT-ATXN7
injected mice with antibodies against ATXN7 and either
MAP-2 (Fig. 3b) or NF (Fig. 3d and f), showed a weak
immunoreactivity at the site of LV injection (where
transgene expression levels are the highest) very likely
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due to local cell loss and subsequent disruption of
both axonal and dendritic networks. As expected, no
alteration in the distribution of MAP-2 (Fig. 3a) and
NF (Fig. 3c and e) was observed after LV-WT-ATXN7
injection.
Because synaptotoxicity has not yet been examined in
rodent models of SCA7, we investigated whether this
pathological feature would be detected in our LV-based
SCA7 mouse model and correlated with MUT ATXN7
accumulation. For this purpose, we carried out immuno-
histochemical staining for the synaptophysin (SYP),
synaptosomal-associated protein 25 (SNAP-25) and
post-synaptic density protein 95 (PSD-95) proteins,
which are all associated to the synaptic compartment.
The immunoreactivity of SYP, SNAP-25 and PSD-95 was
clearly decreased in the LV-MUT-ATXN7 injected cere-
bellar regions (Fig. 3h, j and l, respectively), as compared
to those injected with the LV-WT-ATXN7 (Fig. 3g, i and
k, respectively), which revealed a strong immunoreactiv-
ity of these synaptic markers. Altogether, these results
showed that LV-based delivery of MUT ATXN7 in wild-
type mice induced a loss of PCs as well as synaptotoxicity.
Cerebellar overexpression of MUT ATXN7 induces up-
regulation of inflammation markers
We next studied the consequences of human ATXN7
overexpression over markers accompanying inflamma-
tion. Our results demonstrated that, compared to LV-
WT-ATXN7 injected mice, the animals overexpressing
the LV-MUT-ATXN7 showed a local up-regulation of
markers associated to inflammation, such as the Glial
Fibrillary Acidic Protein (GFAP) astrocytic marker
(Fig. 4b; quantification in S), the microglia/macrophage-
specific calcium-binding protein ionized calcium binding
adaptor molecule 1 (Iba1) (Fig. 4d; quantification in T)
and the cd11b pan-macrophage marker (Fig. 4f ). These
data were supported by additional immunofluorescence
analyses using another anti-GFAP antibody (SMI-25)
and vimentin that revealed intense immunoreactivity in
astrocytes and Bergmann glial cells, respectively, in re-
gions injected with LV-MUT-ATXN7, compared to re-
gions injected with LV-WT-ATXN7 (Fig. 4g–j). In
addition, specific microglial markers, such as the nitric
oxide synthase (iNOS), CD68, the Transforming growth
factor Beta (TGF-ß) and the Triggering receptor
expressed on myeloid cells 2 (TREM2) (Fig. 4k–r) were
shown to be-upregulated in regions injected with LV-
MUT-ATXN7, but not in the cerebella of mice injected
with LV-WT ATXN7.
Lentiviral-mediated overexpression of MUT ATXN7 in the
cerebellum induces ataxic behavioral deficits in mice
To evaluate whether the neuropathological changes in-
duced by MUT ATXN7 overexpression could be trans-
lated into behavioral dysfunction, the animals underwent
two tests of balance and motor coordination, the rotarod
and the locotronic motor tests, that are known to be sen-
sitive to cerebellar dysfunction, at early (2 and 4 weeks)
and late (8 and 12 weeks) disease stages. The spontaneous
activity was also monitored using an automated activity
cage (actimeter) at 12 weeks after injection (Fig. 5).
At an early disease stage (2 or 4 weeks after injection),
no statistically significant difference was found in the
rotarod test for the latency to fall (LF) and the speed
when we compared the LV-MUT-ATXN7 mice and ei-
ther the non-injected or the LV-WT-ATXN7 injected
mice (Fig. 5a and b). At late stages (8 and 12 weeks
post-injection), the overexpression of truncated MUT
ATXN7 in the cerebellum induced a severe loss of
motor coordination, with a statistically significant differ-
ence for the LF and the speed between the LV-MUT-
ATXN7 injected group (LF: 48.7 ± 9.2 s; speed: 18,7 ±
2.04 rpm; n = 8) and either the non-injected mice (LF,
69,75 ± 5,71 s; speed, 25.03 ± 1.88 rpm; n = 6) or the LV-
WT-ATXN7 injected mice (LF = 69,61 ± 11.03 s; speed =
25.06 ± 3.48 rpm; n = 6) at 8 weeks after injection. Simi-
lar data were observed, at 12 weeks after injection, with
a statistically significant difference for the LF and the
(See figure on previous page.)
Fig. 1 Lentiviral-mediated overexpression of truncated human WT ATXN7 and MUT ATXN7 in the mouse cerebellum. a Protocol: lentiviral vectors
(LV) encoding truncated human WT ATXN7 or MUT ATXN7 were injected sterotactically into the mouse cerebellum. The animals were sacrificed
at 2 and 12 weeks post-injection. b Schematic representation of the LV encoding truncated (amino acids 1–230) wild-type (WT ATXN7; 10 CAG
repeats) or mutant (MUT ATXN7; 100 CAG repeats) human ATXN7 (ATXN7) and a GFP tag, under the control of the phosphoglycerate kinase-1
(PGK-1) promoter. c–l and (r–v) Immunohistochemistry and (m–q) immunohistofluorescence in cerebellum. Truncated WT ATXN7 was mainly
nuclear and diffuse in PCs at 2 (D, I and N) and 12 weeks post-injection (E, J and O) (arrows), whereas MUT ATXN7 was nuclear and diffuse at
2 weeks (F and K), with small intranuclear aggregates in PCs (arrows in P) (laser confocal microscopy: ATXN7 in green; DAPI stain, blue). MUT
ATXN7 forms robust intranuclear inclusions in the GCL at 12 weeks (G, L and arrows in Q). Immunohistochemical labeling with anti-GFP showed similar
results (R-V). No transgenic ATXN7 immunoreactivity was observed in mice injected with PBS (C, H and M). w Representative western-blot of cerebellar
lysates: overexpression of truncated WT ATXN7 and MUT ATXN7, 2 weeks post-injection, probed with an anti-ATXN7 antibody that recognizes
both endogenous mouse and human ATXN7. Non-injected cerebella (NI) were used as control: human WT ATXN7 expression was ~30-fold
higher than endogenous mouse ATXN7 (analysis by optical densitometry). ATXN7-positive aggregates were retained in the stacking gel
(SDS-insoluble fraction) and a robust smear of putative cleavage fragments was observed in MUT ATXN7 but not in WT ATXN7-injected
animals. Bars: C–G: 50 μm; H–L: 20 μm; M–Q: 10 μm; R–V: 20 μm
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speed between the LV-MUT-ATXN7 injected group (LF:
43.5 ± 12 s; speed: 17 ± 3.7 rpm; n = 8) and either the
non-injected mice (LF: 78.2 ± 11 s; speed, 27.8 ± 5 rpm;
n = 6) or the LV-WT-ATXN7 injected mice (LF = 74.5 ±
13.9 s; speed = 26.56 ± 4.3 rpm).
The locomotor behavior of the LV-MUT-ATXN7
injected animals was also shown to be severely impaired
in the locotronic test of fine paw motor coordination at
8 and 12 weeks post-injection. No statistically significant
difference was found at 2 and 4 weeks post-injection
(See figure on previous page.)
Fig. 2 Lentiviral-based overexpression of MUT ATXN7 induces cell loss and degeneration in the mouse cerebellum. a–e Calbindin immunostaining
revealed loss of Purkinje cells (PC) in mice injected with an LV-MUT-ATXN7, 2 and 12 weeks post-injection (D and E); in mice injected with PBS or an
LV-WT-ATXN7 no cell loss was observed at either 2 weeks or 12 weeks post-injection (A, B and C). f Quantification: in transduced regions, the number
of calbindin-positive PCs decreased ~19 %, 2 weeks post-injection and ~64 % 12 weeks post-injection in MUT ATXN7 transduced regions, whereas
injection with PBS or overexpression of WT ATXN7 did not affect calbindin-positive PCs. Values are expressed as mean ± standard deviation
(SD). g and h Laser confocal microscopy showing the preservation of calbindin-positive PCs (red) in regions transduced with WT ATXN7 displaying
diffuse immunoreactivity (green) (arrow in G); PCs (red) were depleted in areas transduced with LV-MUT ATXN7, attested by the presence of ATXN7-
positive aggregates (green). i–m Cresyl violet staining showed preservation of PCs and GCL in mice injected with PBS or LV-WT-ATXN7, whereas loss of
PCs and shrinkage of the GCL (L and M) were observed in mice injected with MUT ATXN7, at 2 and 12 weeks post-injection. n–o Quantification of GCL
and ML thickness: overexpression of MUT ATXN7 induced a shrinkage of the GCL (~31 %) (M and N) and ML (~33 %) (M and O) near the injection site,
12 weeks post-injection. PBS injection or overexpression of WT ATXN7 did not affect PCs, the ML or the GCL thickness (I, J, K, N and O). Statistical
analyses of calbindin immunostaining and cresyl violet staining were performed by one-way ANOVA followed by a post-hoc Fisher’s test.
Values are expressed as mean ± standard deviation (SD). p–q Neurotracer staining is decreased in PCs and GCL (Q) in mice injected with
LV-MUT-ATXN7 compared to mice injected with LV-WT-ATXN7 (P). r–s Fluoro-Jade B staining shows increased number of degenerating
neurons in mice injected with LV-MUT-ATXN7 (S) compared to mice overexpressing WT ATXN7 (R). t–u The number of caspase-3-positive
cells increased in cerebellar regions injected with LV-MUT-ATXN7 (U). Bars: A–E: 100 μm; G and H: 100 μm; I–M: 50 μm; P–Q: 20 μm; R–S:
50 μm; T–U: 20 μm
Fig. 3 MUT ATXN7 disrupts cerebellar axonal and dendritic structure and causes synaptotoxicity. Laser confocal microscopy showing loss of
microtubule associated protein 2 (MAP-2) immunoreactivity (red) in the molecular layer, in cerebellar regions injected with LV-MUT-ATXN7 (green)
(b); in regions transduced with WT ATXN7, MAP-2-positive arborizations were preserved (a); high magnification inset: WT ATXN7 immunoreactivity
(green) in the nucleus of PCs with standard MAP-2 immunoreactivity (red) (A). Loss of NF70-kDa (NF: neurofilament) immunoreactivity (green) around
the injection site was observed when MUT ATXN7 (red) was overexpressed in cerebellum (d) and (f). The standard pattern of neurofilaments (NF)
immunoreactivity around PCs and in the GCL was observed in regions (arrows) transduced with WT ATXN7 (c) and (e); high magnification
inset: WT ATXN7 immunoreactivity (red) in PC nuclei with standard NF-immunoreactivity (green) around PCs. Loss of synaptophysin (SYP)
(red) (h), synaptosomal-associated protein 25 (SNAP-25) (red) (j) and postsynaptic density protein 95 (PSD-95) (red) (l) immunoreactivity in
MUT ATXN7-transduced regions (green) (GCL); standard dot-like SYP, SNAP-25 and PSD-95 immunoreactivity was observed in WT ATXN7-expressing
areas (PCs and in GCL) ((g), (i) and (k), respectively). Bars: A–D: 100 μm; E–F: 50 μm; G–L: 10 μm
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between mice injected with the LV-MUT-ATXN7 and
either non-injected or LV-MUT-ATXN7-injected mice,
whereas the number of errors (NE) and the time spent
to cross the bars (TCB) were robustly increased at a
later disease stage (8 and 12 weeks post-injection) in
mice overexpressing the truncated MUT ATXN7
(Fig. 5c and d).
Statistically significant differences were found at
8 weeks post-injection between the LV-MUT-ATXN7
injected group (Number of errors NE = 2.2 ± 1.2; TCB =
17.63 ± 3.86 s; n = 8) and the non-injected (NE = 0.47 ±
0.21; TCB = 10.8 ± 1.08 s; n = 6) or the LV-WT-ATXN7
injected mice (NE = 0.47 ± 0.27; TCB = 10.1 ± 2.03 s; n =
6). Similar results were observed at 12 weeks post-
injection between the LV-MUT-ATXN7 injected mice
(NE = 3.1 ± 1.7; TCB = 21.52 ± 7.76 s; n = 8) and the non-
injected (NE = 0.63 ± 0.39; TCB = 10.6 ± 1.62 s; n = 6) or
the LV-WT-ATXN7injected mice (NE = 0.67 ± 0.79;
TCB = 10.20 ± 2.34 s; n = 6). Although a tendency was
observed for an age-related aggravation of the pheno-
type between 8 and 12 weeks after LV-MUT-ATXN7
injection, the difference in performance between 8
and 12 weeks did not reach statistical significance
(Fig. 5c and d). No statistically significant difference
was found between non-injected mice and WT
ATXN7 overexpressing mice at any time-point of the
study (Fig. 5c and d).
Finally, the behavioral effects of MUT ATXN7 over-
expression were analyzed by monitoring spontaneous
motor activity in an actimeter during 45 min at
12 weeks post-injection (Fig. 5e–l). Again, the animals
injected with LV-MUT-ATXN7 differed significantly
from LV-WT-ATXN7-injected or non-injected mice,
with an overall decrease of activity. Statistically
Fig. 4 Cerebellar overexpression of MUT ATXN7 induces immunoreactivity of markers of inflammation. a–f Cerebellum injected with LV-MUT-ATXN7
shows increased GFAP (B), Iba1 (microglia) (D) and cd11b (F) immunoreactivity compared to a cerebellum injected with WT ATXN7 (A, C and
E, respectively). g–r Laser confocal microscopy shows increased astrocytic immunoreactivity (SMI-25 staining; green) in cerebellar regions
transduced with MUT ATXN7 (H) compared to control regions injected with WT ATXN7 (G); Anti-vimentin staining (green) shows increased
immunoreactivity of Bergmann glial cells in the cerebellar ML transduced with MUT ATXN7 (J) relatively to the ML transduced with WT ATXN7
(I). The increased immunoreactivity of the microglial markers NOS2 (L), CD68 (N), TGF-ß (P) and TREM2 (R) (in green) is observed in cerebellar
regions overexpressing MUT ATXN7, compared to regions overexpressing WT ATXN7 (K, M, O and Q, respectively). s and t Quantification showing
increased GFAP-positive immunoreactivity (S) and Iba1-positive immunoreactivity in the cerebellum of mice injected with LV encoding MUT ATXN7
(n = 4), relatively to WT ATXN7-injected mice (n = 4); Student’s T test. Values are expressed as mean ± standard error of the mean (SEM). Bars: A–D:
200 μm; E and F: 50 μm; G–J: 50 μm; K–R: 20 μm
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significant differences were observed between LV-
MUT-ATXN7 and either LV-WT-ATXN7 injected or
non-injected mice in the total activity time (1510 ±
259 s, 1901 ± 103 s and 1958 ± 109 s, respectively)
(~20 % of decrease), global movements (1243 ± 262 s,
1602 ± 130 s and 1673 ± 120 s, respectively) (~22 % of
decrease), the percentage of low (31.9 ± 4.7, 39.67 ± 1.86
and 40.5 ± 2.35 %, respectively) (~20 %) and high speed
(13 ± 5.13, 19 ± 3.63 and 20.67 ± 3.67 %, respectively)
(~31.5 %) movements, the average speed (3.63 ±
0.43 cm/s, 4.17 ± 0.34 cm/s and 4.1 ± 0.3 cm/s, respect-
ively) (~12 %) and the total distance traveled (4598 ±
1466 cm, 6682 ± 994 cm and 6898 ± 979 cm, respect-
ively) (~31 %). No statistically significant difference was
Fig. 5 Lentiviral-mediated MUT ATXN7 overexpression in the mouse cerebellum induces locomotor abnormalities. Performance on the accelerating
rotarod showed reduced motor coordination at 8 and 12 weeks, but not at 2 or 4 weeks post-injection in mice injected with LV-MUT-ATXN7 (a-latency
to fall; b-speed at falls), relative to non-injected mice or mice injected with LV-WT-ATXN7. The locotronic test shows an increased number of errors (c)
and time to cross the bar (d) in mice injected with LV-MUT-ATXN7, relatively to non-injected mice or mice receiving LV-WT-ATXN7, at 8 and 12 weeks
post-injection. Measure of actimetry: total active time decreased (~20 %) (e) and inactive time increased (f), but no statistically significant changes in
total immobility (g) were observed in mice injected with MUT ATXN7. These mice also displayed reduced global movements (~22 %) (h), low (~20 %)
(j) and high speed movements (~31.5 %) (i), average speed (~12 %) (k) and total distance traveled (~31 %) (l) during 45 min recording, compared to
non-injected mice or mice injected with LV-WT ATXN7. The performances of mice injected with LV-WT-ATXN7 or non-injected mice were similar in
all tests. Statistical analysis for actimetry assessment was performed using one-way ANOVA followed by a post-hoc Fisher’s test. Statistical
analysis for behavior assessment in the rotarod and locotronic tests was performed using Two-way ANOVA followed by a post-hoc Fisher’s
test. Number of animals; n = 6 for non-injected, n = 6 for WT ATXN7 and n = 8 for MUT ATXN7 injected mice.
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found between LV-WT-ATXN7 injected and non-injected
mice (Fig. 5e–l).
Nuclear MUT ATXN7 inclusions sequester FUS/TLS and
accumulate phosphorylated TDP-43
Next, we investigated whether in vivo ATXN7 accumula-
tion in the nucleus affected two RNA binding proteins:
the transactive response DNA binding protein 43-kDa
(TDP-43) and the Fused in sarcoma (FUS/TLS). Im-
munofluorescence revealed that, in the LV-based model
of SCA7, there was no clear co-aggregation between
MUT ATXN7 and endogenous TDP-43, which remained
diffuse in the nucleus (Fig. 6b). However, ~12 % of mu-
tant ATXN7-positive aggregates contained pathological
phosphorylated TDP-43 (p-TDP-43) (Fig. 6d), which was
absent when truncated WT ATXN7 was overexpressed
in the cell nucleus (Fig. 6c). On western-blots biopsies
from regions infected with truncated MUT ATXN7, re-
vealed by anti-phosphorylated TDP-43, a ~25-kDa band
was increased ~1.6-fold compared to samples from non-
injected mice or mice injected with LV-WT-ATXN7
(Fig. 6e and g). We next examined FUS/TLS expression
in our LV-based model of SCA7. FUS/TLS and ATXN7
co-localized in ~70 % of intranuclear inclusions at
12 weeks post-infection (Fig. 6i). MUT ATXN7 overex-
pression also decreased the diffuse staining of endogen-
ous FUS/TLS within the nucleus of granule cells
(Fig. 6k); when truncated WT ATXN7 was overex-
pressed in PCs, FUS/TLS stained the cell nucleus, but
did not form FUS/TLS-positive aggregates (Fig. 6h). En-
dogenous levels of FUS/TLS also decreased (~50 %) on
western-blots of brain samples from cerebellar regions
expressing truncated MUT ATXN7 (Fig. 6l and m) com-
pared to samples from non-injected mice or WT
ATXN7-injected mice.
Interestingly, similar results to those obtained in the
LV-SCA7 model were found in Atxn7100Q/5Q KI mice
(Additional file 1: Figs. S4 and S5). Although more p-
TDP-43-positive dots were detected in the nucleus of
PCs of Atxn7100Q/5Q KI mice compared to controls
(Additional file 1: Fig. S4A), the levels of normal TDP-
43 controls (data not shown) and phosphorylated TDP-
43 (Additional file 1: Fig. S4B) in cerebellar lysates of
Atxn7100Q/5Q KI mice were similar. Interestingly, a ~25-
kDa band labeled by the anti-phosphorylated TDP-43
antibody migrated more slowly in samples from
Atxn7100Q/5Q KI mice compared to control samples
(Additional file 1: Fig. S4B). Moreover, these data were
completed with additional immunofluorescence that re-
vealed that FUS/TLS and mutant ATXN7 co-aggregated
in the nucleus of PCs, accompanied by loss of endogenous
FUS/TLS immunoreactivity compared to age-matched
controls (Additional file 1: Fig. S5A). Western-blot ana-
lyses of whole cerebellar lysates from Atxn7100Q/5Q KI
mice also revealed a ~33 % decrease in the levels of sol-
uble FUS/TLS protein (Additional file 1: Fig. S5B and C).
MUT ATXN7 specifically traps the MBNL1 protein in the
mouse cerebellum
To investigate whether the muscleblind-like proteins 1
and 2 (MBNL1 and/or MBNL2) RBPs could be impli-
cated in SCA7 pathology we analyzed the effects of
MUT ATXN7 overexpression on these specific RBPs in
the cerebellum of LVs-injected mice. Immunofluores-
cence studies showed that MBNL1 co-aggregated within
MUT ATXN7 inclusions in the PC nuclei of LV-MUT-
ATXN7 injected mice (~80 %) (Fig. 7b), in contrast to
the diffuse MBNL1 and ATXN7 staining in LV-WT-
ATXN7 injected mice (Fig. 7a). Strikingly, no MBNL2
co-aggregation was found with ATXN7 in the cerebel-
lum of LV-MUT-ATXN7 injected mice (Fig. 7c), strongly
suggesting that MBNL1 is specifically trapped into MUT
ATXN7 inclusions. We further analyzed the levels of
expression of the MBNL1 and MBNL2 proteins by
western-blot analysis of cerebellar lysates from mice
injected with the LV-encoding truncated WT ATXN7
and MUT ATXN7. In mice injected with LV-MUT-
ATXN7, we observed a slight increase in the levels of
the MBNL1 ~ 35-kDa band relatively to LV-WT-ATXN7
injected mice (Fig. 7d). In addition, a strong increase in
the levels of two additional bands around 25-kDa and
~55-kDa, maybe corresponding to different cerebellar
MBNL1 isoforms [30], was observed in LV-MUT-ATXN7
injected mice compared to LV-WT-ATXN7 injected mice.
(Fig. 7d–g). Interestingly, no difference was observed in
the levels of the MBNL2 protein that showed a similar
~35-kDa doublet band in both the LV-WT-ATXN7 and
LV-MUT-ATXN7 injected mice (Fig. 7h and i). Similar re-
sults were found by immunofluorescence in brain cerebel-
lar slices (Additional file 1: Fig. S6A) and in western-blot
analyses comparing MBNL1 and MBNL2 levels in cere-
bellar lysates from Atxn7100Q/5Q KI mice and controls
(Additional file 1: Fig. S6B-G), strongly supporting our
findings and excluding a possible artefactual effect of LV-
mediated ATXN7 overexpression .
Immunoreactivity of TDP-43, FUS-TLS, MBNL1 and MBNL2
in the cerebellum of SCA7 patients
To conclude the study, we investigated the immunoreac-
tivity of TDP-43, FUS/TLS and muscleblind-like pro-
teins 1 and 2 in the cerebellum of SCA7 patients and
controls. In SCA7 patients, nuclear immunoreactivity for
TDP-43 in PCs was more pronounced than in control
PCs, where TDP-43 immunoreactivity was more diffuse
(Fig. 8a). The phospho-TDP43 antibody strongly labeled
the nucleus of PCs and granule cells in the cerebellum
of SCA7 patients whereas labeling in PC nuclei and cyto-
plasm was only faint in controls (Fig. 8b). Immunolabeling
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Fig. 6 Phosphorylated TDP-43 and FUS/TLS accumulate in the cerebellum of the LV-mouse model of SCA7. Laser confocal microscopy showing that
murine TDP-43 (red) remains diffuse in a Purkinje cell transduced with WT ATXN7 (green) at 12 weeks post-injection (a). Murine TDP-43 (red) does not
co-aggregate in MUT ATXN7-positive inclusions (green) at 12 weeks post-injection (b). Partial co-localization of MUT ATXN7 (green) and phosphorylated
TDP-43 (red) (~12 %) was observed in GCL (d); nuclear WT ATXN7 (green) does not co-localize with phosphorylated TDP-43 (c) in PCs (n=5). e Representative
western-blot of cerebellar lysates shows a ~1.6-fold increased level of a 25-kDa band of phosphorylated-TDP-43 in mice injected with LV-MUT-ATXN7
compared to non-injected mice or mice injected with LV-WT-ATXN7 (n = 3). f and g Optical densitometry was normalized according to the amount of
actin loaded in the corresponding lane. A partition ratio was calculated and expressed as optical densitometry (arbitrary units) relative to the sample
with highest value for the normalization control set at 1. Values are expressed as mean ± standard error (SEM) of the mean. *p≤ 0.05 (one-way ANOVA).
All data are from 3 mice/group. h–k Laser confocal microscopy showing co-aggregation of MUT ATXN7 (green) and FUS/TLS (red) in GCL in mice
injected with LV-MUT-ATXN7 (69.6 ± 7.4 %), 12 weeks post-injection (I); in regions transduced with WT ATXN7 co-localization of WT ATXN7 with diffuse
FUS/TLS in GCL, but no aggregation is observed (H). In the GCL transduced with MUT ATXN7, FUS/TLS is trapped into the ATXN7 inclusion and diffuse
nuclear FUS/TLS fluorescence was decreased (see arrow) (K); in the contrary, in the non-transduced GCL (J) or in PCs transduced (H) with WT ATXN7
(green), FUS/TSL immunoreactivity was diffuse as well as WT ATXN7 in PCs (H). l Representative western-blot of cerebellar lysates shows reduced
FUS/TLS levels (~50 %) (L) in mice injected with LV-MUT-ATXN7 compared to non-injected mice or mice injected with LV-WT-ATXN7 (n = 3). m Optical
densitometry was normalized as indicated in panel F and G. Values are expressed as mean ± standard error (SEM) of the mean. *p≤ 0.05 (Student’s
T test). All data are from 3 mice/group. Bars: A–D: 20 μm; H and I: 10 μm; J and K: 3 μm
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of FUS/TLS was easily detectable in small granules in
the nucleus of PCs in the cerebellum of SCA7 patients
but not in controls (Fig. 8c). The MBNL1 protein accu-
mulated in shrunken PC nuclei in SCA7 patients but
not in controls, where it was almost not detectable
(Fig. 8d). MBNL2 immunoreactivity increased in the
nucleus, but also in the cytoplasm of SCA7 PCs com-
pared to controls, where low MBNL2 immunoreactivity
was cytosolic (Fig. 8e). These results confirm the abnor-
mal accumulation of these RBPs in cerebellar PCs from
SCA7 patients, which is in accordance with the LV-
based model of SCA7.
Fig. 7 MUT ATXN7 specifically traps MBNL1 but not MBNL2 in the mouse cerebellum. a–c Laser confocal microscopy in cerebellum shows
co-aggregation of MUT ATXN7 (green) and MBNL1 (red) in aggregates (~80 %) in the the GCL (B); no MBNL1 aggregation was observed
in WT ATXN7-expressing PCs (A). The MBNL2 protein was not trapped in nuclear MUT-ATXN7 aggregates (C). d Representative western-blot
of cerebellar lysates shows increased levels of the MBNL1 protein (55 kDa, 35 kDa and 25 kDa) in a mouse overexpressing MUT ATXN7 compared to a
mouse overexpressing the control WT ATXN7 (n = 3). H) Western-blot: no differences in MBNL2 protein levels were observed in the cerebella of mice
injected with LV-WT-ATXN7 or LV-MUT-ATXN7 (n = 3). Tubulin was used as a loading control. e, f, g and i Optical densitometry was normalized
according to the amount of tubulin loaded in the corresponding lane. A partition ratio was calculated and expressed as optical densitometry
(arbitrary units) relative to the sample with highest value for the normalization control set at 1. Values are expressed as mean ± standard error (SEM)
of the mean. *p≤ 0.05 (Student’s T test). All data are from 3 mice/group. Bars: A–C: 10 μm
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Discussion
When expressed in the cerebellum of transgenic/knock-
in mice, mutant ATXN7 was reported to cause severe
ataxic symptoms, but no significant cell loss [8, 15]. The
local overexpression of mutant proteins using viral vec-
tors has been successfully used to model neurodegenera-
tive diseases [17, 18, 31–33]. In the present study, we
demonstrated that LV-mediated delivery of mutant
ATXN7 provided an alternative animal model of SCA7,
with the development of an earlier, more robust and ag-
gressive behavioral /histopathological phenotype than
that observed in other SCA7 models [8, 14, 34]. It is,
therefore, a time- and cost-effective animal model of
SCA7 that partially avoids the limitations previously en-
countered, such as the slow development of the disease
and the absence of neurodegeneration.
Remarkably, truncated fragments were shown to accu-
mulate in SCA7 transgenic models, even when they ex-
press the full-length expanded form of ATXN7. An ∼
55 kDa ATXN7 amino-terminal fragment was identified
in both SCA7 transgenic mice and SCA7 patients [8].
Importantly, it has also been observed, in in vitro studies
on SBMA, that full-length polyQ proteins aggregate, but
at a much slower rate than their proteolytic fragments
[35]. Protein proteolytic cleavage mediated by caspases
produces small, polyQ-containing fragments with in-
creased cellular toxicity [36]. The products of proteolytic
cleavage are often found in aggregates, hallmarks of
polyQ diseases, observed in both in vitro and in vivo
models [37] and also in patients post-mortem tissue
[38]. Therefore, we overexpressed, locally in the mouse
cerebellum, an ATXN7 fragment similar in size to the
cleaved fragments previously reported [8, 14, 34]. Indeed,
the local LV-mediated overexpression of an ATXN7 frag-
ment with an expanded polyQ repeat induced a cascade
of events with progressive cell loss and a severe neuro-
pathological phenotype. Furthermore, the local overex-
pression of mutant ATXN7 allowed us to dissect the
specific contribution of SCA7-induced cerebellar patho-
physiology, since other brain regions, such as the brain-
stem and substantia nigra, were also reported to be
affected in this pathology [28]. This model may therefore
be of use not only to dissect molecular mechanisms of
SCA7 pathogenesis, but also to investigate in vivo new
therapeutic strategies acting on cell degeneration and be-
havioral abnormalities. Importantly, SCA7 overexpression
could be investigated at different time-points and SCA7
severity could be modulated by varying the dose of LV to
be injected, as previously described in a LV-based rat
model of SCA3 [17, 18].
Our first results showed that intracerebellar injection
of LV encoding either wild-type or mutant truncated hu-
man ATXN7 resulted in strong and widespread trans-
gene expression in the cerebellum. However, wild-type
truncated ATXN7 was diffusely distributed throughout
the Purkinje and granule cell nuclei, whereas mutant
ATXN7 progressively accumulated in dense neuronal
intranuclear aggregates and was depleted from the
Fig. 8 Immunoreactivity of TDP-43, FUS/TLS, MBNL1 and MBNL2
in the cerebellum of control and SCA7 patients. Representative
immunohistochemically labelled cerebellar sections (counterstained
with hematoxylin) from a SCA7 patient and a control with no
neurological disease. a TDP-43 immunoreactivity was increased in the
nucleus of PCs in the cerebellum of a SCA7 patient compared
to control PCs where it remained diffuse with few TDP-43 dots.
b Phosphorylated TDP-43 was strongly labeled in the nucleus of
a PC of a SCA7 patient; only rare nuclear granules were observed in the
nucleus of control PCs. c FUS/TLS shows increased immunoreactivity
with FUS/TLS-positive small dots in the nucleus of a PC in a SCA7
patient compared to a control PC where FUS/TLS was almost not
detectable in the nucleus. d Nuclear accumulation of the MBNL1
protein was higher in an atrophic PC in a SCA7 patient compared
to PCs from a control. e MBNL2 diffuse immunoreactivity is increased
in the nucleus and cytosol of a SCA7 PC, compared to control PCs
where MBNL2 immunoreactivity is low in the cytoplasm and almost
undetectable in the nucleus. Bars: 20 μm
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cytoplasm, as in previous SCA7 transgenic/knock-in
models [8, 15]. Importantly, nuclear localization of mu-
tated polyQ protein was proposed to be critical for the
initiation of neuronal death in rodent SCA1 and SCA3
models [39, 40], suggesting that the nuclear environment
of ATXN7 might be important for disease progression.
Our study is in agreement with previous studies, as only
transgenic nuclear mutant ATXN7 leads to PC loss, re-
duced thickness of the granule cell and molecular layers,
12 weeks post-injection, and co-aggregation with RBPs,
whereas transgenic wild-type ATXN7, although nuclear,
did not affect PC or other cerebellar layers.
In the present LV-based model of SCA7, the initial
step in ATXN7 aggregation was visible 2 weeks post-
injection in still well preserved PCs and GCL whereas,
at the late stage of the disease, the mutant protein was
completely aggregated in GCL but not in PCs, suggest-
ing that: (i) the progressive accumulation of insoluble
ATXN7 leads to time-dependent neuronal demise; (ii)
the dynamics and toxicity of aggregate formation may
vary considerably in different cell types from the same
brain region; (iii) PCs appear to be more vulnerable than
cells from the GCL, thus reproducing general features of
human SCA7 pathophysiology [28]. Strong ATXN7 im-
munoreactivity is found widely throughout the GCL but
not in PCs in SCA7 patients, whereas nuclear inclusions
are infrequent, probably due to privileged PC loss [28].
Indeed, PCs can be injured by slight insults in compari-
son with other cells [41], and functional deficits of these
cerebellar nerve cells, in particular, calbindin loss, are
directly associated with compromised control of motor
coordination [42, 43], such as in mice infected with
mutant ATXN7. In this LV-SCA7 model we could also
highlight the loss of synaptic markers, which has not
been previously demonstrated in animal models of
SCA7, as well as the increased immunoreactivity found
in astrocytic and glial cells that may be interpreted as
associated to pathogenesis and/or an adaptative im-
mune response against excitotoxicity induced by mu-
tant ATXN7.
This LV-based model of SCA7 also enabled investigation
of neurodegenerative mechanisms. Indeed, the most stud-
ied mechanisms of pathogenesis were centered on the
abnormal aptitude of mutant proteins to attract cellular
proteins, such as ubiquitin, proteasome components, tran-
scription factors and chaperones, in aggregates causing
loss of the homeostasis by means of primary proteinopa-
thy. As in our LV-based model of SCA7, several SCA7 ro-
dent models [14, 15], which replicate many features of the
human condition, and brains from SCA7 patients [11, 44]
display abundant inclusions that consistently stain posi-
tively for proteasome subunits, ubiquitin, and molecu-
lar chaperones. Indeed, overexpressed mutant ATXN7
sequesters autophagy-related proteins, as previously
described in a SCA7 knock-in model [29], and molecu-
lar chaperones (data not shown), important for the
maintenance of cell homeostasis, depleting them from
neurons. This clearly reflects impaired protein clear-
ance pathways.
In the last few years, it has been shown that RNA-
related mechanisms may play an important role in
polyQ disorders [13]. However, information is scarce
concerning events implicating specific RBPs in animal
models of polyQ disorders, including SCA7. Our find-
ings suggest a direct link between impaired protein deg-
radation and accumulation of misfolded ATXN7 that
sequesters other molecules, such as particular RBPs, de-
pleting them [21] and/or promoting the expression of
aberrant, misregulated isoforms [45]. Studies in in vitro
models and transgenic mouse models demonstrate that
expanded polyQ proteins are more toxic when translo-
cated into the nucleus [46], suggesting that the nucleus
is a crucial site of pathogenesis in polyQ disorders.
Recently, the RBPs FUS/TLS and TDP-43 were shown
to co-localize in nuclear Gems implicated in spliceosome
maintenance [47]. FUS/TLS shares several structural
and functional properties with TDP-43; both are genetic-
ally related to ALS and FTLD, and are nuclear proteins
with RNA and DNA binding abilities that play a role in
RNA splicing- reviewed in [48]. FUS/TLS binds strongly
to SCA1, SCA2, HD and DRPLA aggregates [20, 21, 49].
In addition, several variants of the gene have been iden-
tified as risk factors for ALS and rare forms of FTLD
[50], suggesting that FUS/TLS plays a role in neurode-
generative diseases. In our LV-based model and in
SCA7100Q/5Q knock-in mice, we observed a strong co-
localization between ATXN7 and FUS/TLS in aggre-
gates. To our knowledge, this is the first study reporting
an association between ATXN7 and FUS/TLS and a
decrease in FUS/TLS expression that may result from
sequestration in inclusions. This suggests that an inad-
equate supply of this protein could result in abnormal
transcription, RNA processing and transport, and poten-
tially cause instability of dendritic spines, as observed in
R6/2 HD mice [51]. Notwithstanding, further studies are
needed to elucidate the exact mechanism. Importantly,
primary neurons from FUS/TLS-deficient mice have a
decreased number of spines, and those remaining have a
non-standard morphology [52], indicating that FUS/TLS
is important for neuronal function. Remarkably, we also
show that FUS/TLS is preferentially trapped in ATXN7
inclusions compared to TDP-43. In accordance with our
results, FUS/TLS co-localized with polyQ proteins in
neuronal intranuclear inclusions in SCA2 whereas TDP-
43 did not [53]. TDP-43 also co-localized with hunting-
tin in dystrophic neurites and intracellular inclusions,
but not in intranuclear inclusions [54]. Secondary TDP-
43 proteinopathies have been described in other CAG
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repeat disorders, such as SCA2 [55], SCA3 [56] and HD
[54], suggesting that these disorders might share with
ALS some pathological mechanisms involving TDP-43.
In our LV model and in SCA7 patients, a few neurons
stained positively for p-TDP43 pS409/410, which was
confirmed to be a valuable tool for detecting abnormal
TDP-43 in patients and to evaluate TDP-43 proteinopa-
thies in animal models of neurodegenerative disorders
[57]. Furthermore, phosphorylation of aggregated TDP-43
at S409/410 is a defining hallmark of TDP-43 proteinopa-
thies, including ALS and FTLD-TDP [58, 59]. Phosphoryl-
ation of TDP-43 at serines 409 and 410 was recently
reported to promote TDP-43 toxicity in vivo [60]. Excit-
ingly, in SCA7100Q/5Q knock-in mice, we observed a
hyperphosphorylated ~25-kDa species that could poten-
tially be generated from alternative translational or spli-
cing mechanisms, as previously suggested [57, 61].
Further studies will be needed to better understand the
contribution of TDP-43 to SCA7 pathogenesis.
Nevertheless, whether the accumulation of the RBP
MBNL1 contributes to pathology or is simply an epiphe-
nomenon, in addition to other features of polyQ patho-
physiology, will need further investigations. In this LV
model of SCA7, as well as in Atxn7100Q/5Q KI mice and
SCA7 patients, MBNL1 co-localized with ATXN7 inclu-
sions. In addition, the specific accumulation of MBNL1
in ATXN7 inclusions was associated with an increased
level of MBNL1 in both SCA7 mouse models compared
to wild-type mice. In contrast, MBNL2 did not co-
localize with ATXN7 in inclusions and its level remains
unchanged. The consequences of MBNL1 accumulation
in abnormal proteinaceous inclusions remain to be eluci-
dated. It may be associated with neurotoxicity, although
recent data also suggest that MBNL proteins might be
potential modifiers of polyQ disorders, given that
MBNL1 suppresses the expression of polyQ-containing
proteins [62]. The mechanism leading to the specific
accumulation of MBNL1 in ATXN7 inclusions remains
unknown. It would be of interest to modulate the LV-
SCA7 model by overexpressing or knocking-out these
RBPs to assess their impact on SCA7 pathology, in par-
ticular on aggregate formation, but also to determine
how they affect neuronal markers and inflammation.
To conclude, the complete elucidation of these mecha-
nisms will be important for understanding SCA7 and
related polyQ disorders and the development of poten-
tial therapeutics.
Conclusions
This study validates a novel LV-based SCA7 mouse
model, in which strong and sustained expression of
MUT ATXN7 in the cerebellum was found sufficient to
generate motor defects. This model can be further
exploited to better understand the importance of RBPs
in RNA/protein-mediated neuropathology and to evalu-






100Q-GFP-WPRE transfer plasmids were constructed by
sub-cloning two previously described truncated versions
of the human SCA7 (Gene ID: 6314) cDNA (amino
acids 1–232) [11], encompassing 10 glutamines (wild-
type, WT ATXN7-10Q) or 100 glutamines (mutant,
MUT ATXN7-100Q) into a HIV-1 derived vector plas-
mid, containing a GFP reporter gene at the 5’ end
(pRRL-SIN-cPPT-PGK-GFP-WPRE) and an added NLS
derived from the SV40, placed under control of the
phosphoglycerate kinase 1 (PGK-1) promoter.
Stocks of VSV-G pseudotyped self-inactivating lenti-
viral vectors were produced in 293 T cells using a four-
plasmid system as described previously [65]. The LV
particles were concentrated by ultracentrifugation and
resuspended in phosphate-buffered saline (PBS). Vector
titers (expressed in TU/ml) were determined by quanti-
tative PCR amplification (SybRGreen detection) 4 days
post-transduction in HCT116 human fibroblastic cells
with serial dilutions of vector. Viral stocks were stored
at−80 °C until use.
Animals
Four-week-old female C57BL/6 mice (Charles River, Les
Oncins, France) weighing ~15–17 g were injected into the
cerebellum with LV encoding truncated wild-type or trun-
cated mutant human ataxin-7. Heterozygous SCA7100Q/5Q
knock-in female mice (hereafter called SCA7 KI mice) car-
rying 100 CAG repeats in the mouse Sca7 locus [16] on
the pathological allele derived from the SCA7266Q/5Q [15]
were also used. SCA7 KI mice were analyzed at 12 months
of age (n = 4) (late stage disease) and compared to 12-
month-old (n = 4) wild-type littermates. Animals were
housed in a temperature-controlled room and maintained
on a 12 h light/dark cycle. Food and water were available
ad libitum. The experiments were carried out in accord-
ance with the European Community Council directive
(86/609/EEC) for the care and use of laboratory animals
and were approved by the Commission Génie Génétique
of the French Ministry for Scientific Research and
Education.
In vivo injection of lentiviral vectors in the mouse
cerebellum
Wild-type mice were anesthetized by administration of
ketamine (75 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.)
and injected stereotactically into the vermis with LVs
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encoding the green fluorescent protein (GFP) (n = 3), hu-
man truncated wild-type ataxin-7 (WT ATXN7; ATXN7-
10Q) (n = 9) or human truncated mutant ataxin-7 (MUT
ATXN7; ATXN7-100Q) (n = 11). LVs were injected into
the mouse cerebellum through a 34-gauge blunt-tip nee-
dle linked to a Hamilton syringe (Hamilton, Reno, NV,
USA) by a polyethylene catheter. The viral suspensions
(3×106 TU/ml) were injected at 0,25 μl/min using an
automatic injector (Stoelting Co., Wood Dale, USA).
Three μl of LV suspension were injected at the fol-
lowing coordinates:−6.5 mm rostral to bregma, 0 mm
lateral to midline, and−1.1 mm ventral from the dura
mater, with the mouth bar set at 0. After injection,
the syringe needle was left in place for an additional
5 min before being slowly raised. The skin was closed
using a 6-0 Prolene® suture (Ethicon, Johnson and
Johnson, Brussels, Belgium).
Histology
Two weeks (n = 3 for LV-GFP; n = 3 for PBS; n = 3 for
LV-WT ATXN7; n = 3 for MUT ATXN7) or 3 months
(n = 6 for LV-WT ATXN7; n = 8 for MUT ATXN7) after
LV injection into the cerebellum, the animals were given
an overdose of sodium pentobarbital and perfused trans-
cardially with a solution of 0.1 M phosphate-buffered sa-
line (PBS) and then with 4 % paraformaldehyde (PFA) in
PBS. The brains were removed, post-fixed in 4 % PFA in
PBS and processed as described previously [27]. See also
Additional file 2.
Immunohistochemistry
Immunofluorescence and 3,3’-Diaminobenzidine (DAB)
staining were carried out as previously described [27].
See also Supplementary materials and methods.
Human SCA7 brain samples
Post-mortem cerebellar tissue from two SCA7 patients
with morphologically and genetically confirmed SCA7
(10 and 36 years of age at death, with 85 and 49 CAG
repeats on the mutant allele in peripheral blood, respect-
ively) and two controls with no evidence of neurological
disease (57 and 72 years of age at death) were obtained






Motor coordination and balance were estimated using a
five station mouse rotarod (Bioseb, Vitrolles, France).
Mice were first trained at increasing speed up to a
constant speed of 16 rpm. Subsequently, the latency to
fall was recorded automatically by incremental speed
starting at 4 rpm and accelerating over a 2 min period
up to 40 rpm, using break technology. Each mouse was
tested 3 times per day (with at least 15 min rest be-
tween the trials) three times a week, at 2, 4, 8 and
12 weeks after LV injection. Statistical analysis of ob-
tained data was performed by calculating the mean
values of each trial for each group (mean of 3 daily tri-
als per week with three trials per day). Data are pre-
sented as the mean ± SD of the latency to fall in each
group and differences between groups were analyzed
at each time using one-way ANOVA followed by a
post-hoc Fisher’s test.
Locotronic test
The locotronic apparatus was used to test fine motor co-
ordination when walking. The mice crossed a 75 × 5 ×
20 cm flat ladder with bars (7 mm in diameter), which
were set 2 cm apart. Infrared photocell sensors situated
above and below the bars monitored paw errors. The
locotronic apparatus was supported by software that
automatically sorted paw errors and directly calculated
the time of the course. The rate of missteps and the time
of the course were assessed in three trials/day for three
consecutive days, with 20 min rest between trials. The tests
were performed at 2, 4, 8 and 12 weeks post-injection. Stat-
istical analysis of obtained data was performed by calculat-
ing the mean of three trials per day over 3 days for each
group. Data are presented as the mean ± SD. Differences
between groups were analyzed at each time using one-way
ANOVA followed by a post-hoc Fisher’s test.
Spontaneous activity
An actimeter system (Activmeter; Bioseb, Vitrolles, France)
was used to measure vibrations within the cage to assess
locomotion. The distance covered, movements and average
speed were measured over a period of 45-min period. The
tests were performed at 12 weeks post-injection. Data are
presented as the mean ± SD. Differences between groups
were analyzed at each time using one-way ANOVA
followed by a post-hoc Fisher’s test.
Western-blot
Mouse cerebella/brainstem were collected and frozen
at−80 °C. Protein extracts (100 μg) were resolved on
7.5 % (ataxin-7), 12 % (FUS/TLS, MBNL1, and
MBNL2) or 15 % [phospho-TDP-43 (pS409/410)]
SDS-polyacrylamide gels. Western-blotting procedures
were performed as previously described [27]. Films were
scanned and optical densities (OD) were measured using
Quantity One 1D image analysis software (version 4.4;
Biorad, Hercules, CA, USA). The optical densities were
normalized with respect to a “standard protein” (actin or
tubulin) migrating in the same lane. A partition ratio was
Alves et al. Molecular Neurodegeneration  (2016) 11:58 Page 16 of 20
calculated and normalized with respect to the sample with
the highest value defined as 1.
Statistical analysis
Statistical analyses for evaluation of differences be-
tween groups for calbindin immunostaining, cresyl
violet staining, and spontaneous motor activity in the
actimeter were performed using One-way ANOVA
followed by a post-hoc Fisher’s test. Statistical analysis
for behavior assessment in the rotarod and locotronic
tests was performed using Two-way ANOVA followed
by a post-hoc Fisher’s test. Optical densities (OD) of
scanned western-blot films and percentage of marker
co-localization in IF studies were analyzed using the
Student’s t-test or One-way ANOVA followed by a
post-hoc Fisher’s test. Significance thresholds were set
at p < 0.05 for all tests.
Additional files
Additional file 1: Fig. S1. Lentiviral-mediated overexpression of the Green
Fluorescent Protein (GFP) in the mouse cerebellum. Fig. S2. Overexpression
of truncated MUT ATXN7 in the mouse cerebellum induces the formation of
ubiquitinated ATXN7 aggregates Fig. S3. Lentiviral-mediated overexpression
MUT ATXN7 in the mouse cerebellum, at 2 weeks post-infection (early time
point). Fig. S4. Phosphorylated TDP-43 expression in the cerebellum
of Atxn7100Q/5Q KI mice. Fig. S5. FUS/TLS is trapped in ATXN7 aggregates
in Atxn7100Q/5Q KI mice. Fig. S6. MBNL1 and MBNL2 immunoreactivity and
expression in the cerebellum of Atxn7100Q/5Q KI mice. (PDF 1053 kb)
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Abbreviations
ALS, amyotrophic lateral sclerosis; ATXN7, ataxin-7; DNA binding protein
43 kDa; FUS/TLS, Fused in sarcoma; HD, Huntington’s disease; KI, knock-in;
LV, lentiviral vector; MBNL1, muscleblind-like 1; MBNL2, muscleblind-like 2;
NIIs, neuronal intranuclear inclusions; PC, Purkinje cell; polyQ, polyglutamine;
Table 1 Antibodies used in western-blot (WB) and immunohistochemical (IHC) analyses
Primary antibodies Source/Reference catalog WB IHC
rabbit anti-ataxin-7 Thermo Scientific/(PA1-749) 1:2000 1:5000
rabbit-anti-ubiquitin Dako/(Z0458) – 1:2000
mouse anti-ataxin-7 (1C1) Provided by Dr Didier Devys 1:5000 1:5000
mouse anti-Calbindin D-28 K Swant/(300) – 1:4000
mouse anti-microtubule-associated Protein 2 (MAP2) Sigma-Aldrich/(M1406) – 1:2000
mouse anti-synaptophysin Abcam/(ab32594) – 1:250
mouse anti-SNAP-25 Abcam/(ab24737-250) – 1:1000
rabbit-anti-PSD-95 Abcam/(ab18258) – 1:1000
rabbit anti-Glial Fibrillary Acidic Protein (GFAP) Dako/(Z0334) – 1:2000
rabbit anti-ionized calcium binding adapter molecule 1 (Iba1) Wako/(019-19741) – 1:3000
rat anti-CD11b/Mac-1 AbD Serotec/(MCA74G) – 1:1000
rabbit anti-GFP Abcam/(ab6556) – 1:5000
rabbit cleaved caspase-3 (Asp175) Cell Signaling/(9664S) – 1:500
mouse anti-neurofilament 70 KDa Millipore/(MAB1615) – 1:1000
rabbit anti-phospho-TDP-43 (pS409/410) Cosmo Bio/(CAC-TIP-PTD-P01) 1:1000 1:3000
rabbit anti-TARDBP (TAR DNA-binding protein 43) Proteintech/(10782-2-AP) – 1:3000
Mouse anti-FUS/TLS(4H11) (Fused in Sarcoma/Translocated in Sarcoma) Santa Cruz/(sc-47711) 1:1000 1:500
rabbit-anti-MBNL1 (Muscleblind-like protein 1) Santa Cruz/(sc-47740) 1:1000 1:500
rabbit-anti-MBNL2 (Muscleblind-like protein 2) Abcam (ab171551) 1:2000 1:500
rabbit-anti-MBNL2 Abcam (ab108519) – 1:500
rabbit anti-tubulin Abcam/(ab134185) 1:5000 –
rabbit anti-iNOS (Nitric oxide synthase) Cayman Chemicals/(160862) – 1:400
rat anti-CD68 Abd serotec/(MCA1957) – 1:500
rabbit anti-TGF-ß (Transforming growth factor beta) Abcam/(ab66043) – 1:1000
rabbit anti-TREM2 (Triggering receptor expressed on myeloid cells 2) R&D systems/(MAB1729) – 1:500
goat anti-vimentin Santa Cruz/(sc-7557) – 1:500
rabbit anti-p62/SQSTM1 (sequestosome 1) BD Biosciences/(610832) – 1:500
mouse anti-actin Abcam/(ab9484) 1:4000 –
mouse anti-SMI-25 Covance/(SMI-25R) – 1:2000
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RBPs, RNA-binding proteins; SCA7, spinocerebellar ataxia type 7; TDP-43,
transactive response
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